Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →Filing growth compares 2021 (23 records) with 2024 (6) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 288 records in scope (CR5), not by the ranked leaders only.
Sterilizing grade filtration sits at the intersection of membrane science, aseptic process validation and drug manufacturing compliance. The dataset behind this page covers 288 published records filed between 2015 and mid-2026, drawn from claims touching bubble point testing, bacterial retention, filter validation, adsorptive product loss, flow decay and extractable profiles — the technical vocabulary regulators and manufacturers actually use when qualifying a sterilizing filter for pharmaceutical use.
The picture that emerges is one of a mature, consolidated field. A small number of assignees built dense patent estates around core filter validation and membrane construction techniques years ago, and the pace of new filing has slowed sharply since. That does not mean the technology is settled — publication lags filing by roughly 18 months, so the most recent years understate real activity — but it does mean anyone entering now is filing into occupied territory rather than open ground.
Two views of the same 288 records: how filing activity has moved year over year, and which IPC subclasses the claims actually fall under.
Filings peaked at 35 in 2017 and have declined since; the -74% move from 23 filings in 2021 to 6 in 2024 marks the last year the trend can be read as complete, since 2025 and 2026 are still filling in under normal publication lag.
B01D (separation processes) appears in 52.8% of the 288 records, confirming membrane and housing claims as the technical core. A61K (26.7%) and A61L (17.4%) show a large share of filings are anchored in the drug formulation or the sterilizing method rather than the filter itself, and G01N (14.2%) reflects how much of the field is validation and testing methodology, not the physical filter.
Shares are the percentage of the 288 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about sterilizing grade filtration and every answer comes back with the patent numbers behind it.
Try EurekaA method for preparing a filling operation that wets each filter element with a defined amount of pharmaceutical liquid before passing the liquid through a filter assembly arranged between a liquid source and a filling device inside a barrier-controlled filling system.Filed by Groninger & Co. GmbH, published 2026-07-16 — illustrative of how recent filings frame sterilizing filtration as part of an integrated aseptic filling process rather than a standalone membrane claim.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2010107503A1 | Removal of microorganisms from fluid samples using nanofiber filtration media | 71 |
| 2 | US5064529A | Apparatus for testing membrane filters | 71 |
| 3 | US20070089489A1 | Methods and systems for integrity testing of porous materials | 66 |
| 4 | US4872974A | Apparatus for testing membrane filters, and for sterilizing liquids with use of membrane filter | 66 |
| 5 | US20130092622A1 | Nanofiber containing composite membrane structures | 65 |
| 6 | US7594425B2 | Methods and systems for integrity testing of porous materials | 57 |
| 7 | US20120091072A1 | Removal of microorganisms from fluid samples using nanofiber filtration media | 50 |
| 8 | EP0139202A1 | Apparatus for testing membrane filters, and apparatus for sterilizing liquids with use of membrane filter | 47 |
| 9 | US20140116945A1 | Nanofiber containing composite structures | 45 |
| 10 | EP1775015A1 | A method of assessing the integrity of a porous material | 36 |
Citation counts favour older filings in any searched corpus — read these as markers of influence on later filers, not as a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Three signals stand out once the ranking, trend and technology composition are read together.
With the leading assignee alone holding 118 records and the top five combined controlling 73.3% of all 288 records in scope, foundational bubble point testing and membrane integrity claims are heavily staked. New entrants competing head-on in filter housing or basic integrity-test design face dense prior art from a handful of established filers.
Filings dropped from 23 in 2021 to 6 in 2024, continuing a decline from the 2017 peak of 35. Several of the largest historical filers show zero filings in the latest tracked year, consistent with a field where the founding wave of patents has already been laid down rather than one still being actively built out.
More than a quarter of the 288 records carry A61K medicinal preparation classes and 17.4% carry A61L sterilising method classes alongside the filtration classification, meaning many patents protect a formulation-plus-filter or process-plus-filter combination rather than a filter component in isolation.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to sterilizing grade filtration, with the prior art for and against each one.
The ranked list covers 39 companies across the 288 records in scope — not a top-50 or top-100 cut, but the entire ranking the dataset returns.
The leading assignee's 118 records are more than double the combined total of the next four ranked entrants, reflecting decades of accumulated filtration and validation patent activity concentrated in one estate.
Filing volume falls off quickly outside the top handful of names: fifth place holds 10 records and tenth place holds 6, meaning the field narrows fast from one dominant filer to a long tail of much smaller portfolios.
Only 10 co-assignee pairs appear across the dataset, and the strongest pairing repeats across multiple records, suggesting joint filing here tends to happen within long-running individual or corporate partnerships rather than broad industry consortia.
| Assignee | Recent year | YoY |
|---|---|---|
| EMD Millipore Corp | 0 | -100% |
| Teva Pharmaceutical Industries Ltd | 0 | — |
| NxStage Medical Inc | 0 | — |
| Entegris Inc | 0 | — |
| TKACIK GABRIEL | 0 | — |
| Baxter International Inc | 0 | — |
| Baxter Healthcare SA | 0 | — |
| KOZLOV MIKHAIL | 0 | — |
The dataset points to a consolidated field with narrow but real gaps. These are the natural next steps for a team deciding whether and where to file.
Before drafting in bubble point testing or bacterial retention, check how the leading assignee's 118 records actually cover the specific test parameters or membrane construction you plan to claim.
Explore assignee portfolios in EurekaC02F and A61J carry the thinnest coverage among the tracked IPC subclasses; a first claim there would need to show clear technical distinction from the dominant B01D filtration hardware art.
Run a white space search in EurekaFiling has cooled since 2017, but 2025-2026 figures are still incomplete under normal publication lag; monitor whether momentum resumes before concluding the field has settled.
Set up filing alerts in EurekaOne assignee holds 118 of the 288 records in this dataset, far ahead of the fifth-ranked filer at 10 records. The top five assignees combined account for 73.3% of all 288 records in scope, and the top ten hold 86.1%. This level of concentration means most foundational filter validation and membrane integrity claims are already staked by a small number of long-established filers.
No — filings peaked in 2017 at 35 and have fallen since, with the last complete comparison showing a drop from 23 filings in 2021 to 6 in 2024, a 74% decline. Several of the largest historical filers show zero filings in the most recent tracked year. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by about 18 months, so a full rebound cannot be ruled out, but the multi-year trend through 2024 is clearly downward.
Separation processes under IPC class B01D appear in 52.8% of the 288 records, making membrane and filter housing design the dominant technical theme. But medicinal preparation claims (A61K, 26.7%) and sterilising method claims (A61L, 17.4%) are also common, showing that many patents combine a filtration element with a drug formulation or a sterilizing process rather than claiming filter hardware alone. Material testing methods (G01N, 14.2%) reflect the significant share of the field devoted to validation methodology.
The thinnest coverage relative to the field's core sits in water and wastewater treatment applications (C02F, 5.2% of records) and containers for medicine (A61J, 4.5%), compared with the 52.8% carrying core B01D separation claims. Extractable/leachable profiling and redundant filtration train design also appear comparatively under-claimed given how often they are referenced in validation practice. A first claim in these areas would need to clearly differentiate from the dense B01D and A61L prior art rather than restate it in a new application context.
With 73.3% of 288 records held by five assignees and 86.1% held by ten, this field shows a steep concentration curve: one dominant filer, a handful of mid-sized portfolios, and a long tail of much smaller filers below tenth place. This pattern is typical of a mature, compliance-driven technology area where core validation and integrity-test methods were established early and later filers largely add incremental process or formulation claims around that core.
Go past this page: query the whole sterilizing grade filtration corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page